Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

References

• KabariaR, KlaassenZ, TerrisMK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016;9:45–52. doi:10.2147/IJNRD.S7591627022296
   PubMed Web of Science ®Google Scholar
• SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• MochH, CubillaAL, HumphreyPA, ReuterVE, UlbrightTM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.02926935559
   PubMed Web of Science ®Google Scholar
• LjungbergB, BensalahK, CanfieldS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.00525616710
   PubMed Web of Science ®Google Scholar
• OudardS, RtE. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev. 2012;38:981–987. doi:10.1016/j.ctrv.2011.12.00922289686
   PubMed Web of Science ®Google Scholar
• MolinaAM, LinX, KorytowskyB, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. 2014;50:351–358. doi:10.1016/j.ejca.2013.08.02124051327
   PubMed Web of Science ®Google Scholar
• BrenneckeP, ArltMJ, CampanileC, et al. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin Exp Metastasis. 2014;31(3):339–349. doi:10.1007/s10585-013-9632-324390633
   PubMed Web of Science ®Google Scholar
• TentlerJJ, TanAC, WeekesCD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338–350. doi:10.1038/nrclinonc.2012.6122508028
   PubMed Web of Science ®Google Scholar
• DeoRC. Machine Learning in Medicine. Circulation. 2015;132(20):1920–1930. doi:10.1161/CIRCULATIONAHA.115.00159326572668
   PubMed Web of Science ®Google Scholar
• YuG, WangLG, HanY, HeQY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.011822455463
   PubMed Web of Science ®Google Scholar
• FranceschiniA, SzklarczykD, FrankildS, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808–15. doi:10.1093/nar/gks109423203871
   PubMed Web of Science ®Google Scholar
• ShannonP, MarkielA, OzierO, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• StuartJM, SegalE, KollerD, KimSK. A gene-coexpression network for global discovery of conserved genetic modules. Science. 2003;302(5643):249–255. doi:10.1126/science.108744712934013
   PubMed Web of Science ®Google Scholar
• BaderGD, HogueCW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2. doi:10.1186/1471-2105-4-2
   PubMed Web of Science ®Google Scholar
• ChinCH, ChenSH, WuHH, HoCW, KoMT, LinCY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl4):S11. doi:10.1186/1752-0509-8-S4-S1125521941
   PubMed Web of Science ®Google Scholar
• PonténF, SchwenkJM, AsplundA, EdqvistPH. The human protein atlas as a proteomic resource for biomarker discovery. J Intern Med. 2011;270(5):428–446. doi:10.1111/j.1365-2796.2011.02427.x21752111
   PubMed Web of Science ®Google Scholar
• QianCN, HuangD, WondergemB, TehBT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009;115(10 Suppl):2282–2289. doi:10.1002/cncr.2423819402071
   PubMed Web of Science ®Google Scholar
• MotzerRJ, BacikJ, MurphyBA, RussoP, MazumdarM. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–296. doi:10.1200/JCO.2002.20.1.28911773181
   PubMed Web of Science ®Google Scholar
• MotzerRJ, BarriosCH, KimTM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. doi:10.1200/JCO.2013.54.691125049330
   PubMed Web of Science ®Google Scholar
• ChoueiriTK, FigueroaDJ, FayAP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21(5):1071–1077. doi:10.1158/1078-0432.CCR-14-199325538263
   PubMed Web of Science ®Google Scholar
• ChristensenJG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007;18(Suppl 10):x3–10. doi:10.1093/annonc/mdm40817761721
   PubMed Web of Science ®Google Scholar
• XieY, ChenZ, ZhongQ, ChenY, ShangguanW, XieW. Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis. Transl Androl Urol. 2021;10(1):300–309. doi:10.21037/tau-20-96933532319
   PubMed Web of Science ®Google Scholar
• JoostenSC, HammingL, SoetekouwPM, et al. Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015;1855(1):1–16. doi:10.1016/j.bbcan.2014.11.00225446042
   PubMed Web of Science ®Google Scholar
• RauschM, RutzA, AllardPM, et al. Molecular and functional analysis of sunitinib-resistance induction in human renal cell carcinoma cells. Int J Mol Sci. 2021;22(12):6467. doi:10.3390/ijms2212646734208775
   PubMed Web of Science ®Google Scholar
• ChenSK, WangYC, LinTY, WuHJ, HuangCJ, KuWC. G-protein-coupled estrogen receptor 1 agonist G-1 perturbs sunitinib resistance-related phosphoproteomic signatures in renal cell carcinoma. Cancer Genomics Proteomics. 2021;18(3):207–220. doi:10.21873/cgp.2025333893075
   PubMed Web of Science ®Google Scholar
• QuL, DingJ, ChenC, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–668. doi:10.1016/j.ccell.2016.03.00427117758
   PubMed Web of Science ®Google Scholar
• Diaz-MonteroCM, MaoFJ, BarnardJ, et al. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer. 2016;115(8):920–928. doi:10.1038/bjc.2016.26327560553
   PubMed Web of Science ®Google Scholar
• SpencerE, JiangJ, ChenZJ. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 1999;13:284–294. doi:10.1101/gad.13.3.2849990853
   PubMed Web of Science ®Google Scholar
• HatakeyamaS, KitagawaM, NakayamaK, et al. Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A. 1999;96(7):3859–3863. doi:10.1073/pnas.96.7.385910097128
   PubMed Web of Science ®Google Scholar
• OrianA, GonenH, BercovichB, et al. SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J. 2000;19(11):2580–2591. doi:10.1093/emboj/19.11.258010835356
   PubMed Web of Science ®Google Scholar
• ZhangB, ZhangZ, LiL, et al. TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling. Nat Commun. 2018;9(1):1423. doi:10.1038/s41467-018-03716-929650964
   PubMed Web of Science ®Google Scholar
• Xinyi LimY, LinH, ChuT, Pin LimY. WBP2 promotes BTRC mRNA stability to drive migration and invasion in triple-negative breast cancer via NFκB activation. Mol Oncol. 2021. doi:10.1002/1878-0261.13048
   Web of Science ®Google Scholar
• ZhongJ, OguraK, WangZ, InuzukaH. Degradation of the transcription factor Twist, an oncoprotein that promotes cancer metastasis. Discov Med. 2013;15(80):7–15. doi:10.1038/s41419-018-0657-z23375009
   PubMed Web of Science ®Google Scholar
• ZhouBP, DengJ, XiaW, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6(10):931–940. doi:10.1038/ncb117315448698
   PubMed Web of Science ®Google Scholar
• ZhengQ, YuJJ, LiC, LiJ, WangJ, WangS. miR-224 targets BTRC and promotes cell migration and invasion in colorectal cancer. 3 Biotech. 2020;10(11):485. doi:10.1007/s13205-020-02477-x
   Google Scholar
• ZhouDD, LiHL, LiuW, et al. miR-193a-3p promotes the invasion, migration, and mesenchymal transition in glioma through regulating BTRC. Biomed Res Int. 2021;2021:8928509. doi:10.1155/2021/892850933628829
   PubMed Web of Science ®Google Scholar
• BertheletJ, DubrezL. Regulation of apoptosis by inhibitors of apoptosis (IAPs). Cells. 2013;2(1):163–187. doi:10.3390/cells201016324709650
   PubMedGoogle Scholar
• LazzariE, MeroniG. TRIM32 ubiquitin E3 ligase, one enzyme for several pathologies: from muscular dystrophy to tumours. Int J Biochem Cell Biol. 2016;79:469–477. doi:10.1016/j.biocel.2016.07.02327458054
   PubMed Web of Science ®Google Scholar
• MaxwellPH, DachsGU, GleadleJM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1997;94(15):8104–8109. doi:10.1073/pnas.94.15.81049223322
   PubMed Web of Science ®Google Scholar
• MaynardMA, OhhM. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol. 2004;24(1):1–13. doi:10.1159/00007534614654728
   PubMed Web of Science ®Google Scholar
• BaldewijnsMM, van VlodropIJ, VermeulenPB, SoetekouwPM, van EngelandM, de BruïneAP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221(2):125–138. PMID: 20225241. doi:10.1002/path.268920225241
   PubMed Web of Science ®Google Scholar